newsfilter
← Latest News
Business Wire·

New Case Study Highlights Ability of bioAffinity Technologies' CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer

BIAFBIAFW
  • bioAffinity Technologies released a clinical case study where CyPath® Lung test results supported a noninvasive surveillance strategy for a 79-year-old female with a suspicious lung nodule.
  • The patient, a smoker with COPD & coronary heart disease, had a spiculated nodule detected during an LDCT scan in June 2025.
  • CyPath® Lung test results were negative, indicating low malignancy risk & allowing the medical team to defer an invasive biopsy.
  • A follow-up LDCT scan in October 2025 showed the nodule had resolved, validating the decision to avoid unnecessary procedures.
  • The noninvasive test demonstrated 92% sensitivity, 87% specificity, & 88% accuracy for detecting lung cancer in small nodules under 2 centimeters.
  • CyPath® Lung uses advanced flow cytometry & proprietary AI to identify malignancy-indicating cell populations in patient sputum.
  • The test is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
  • Physicians utilized the test to stratify risk & provide objective data for managing high-risk patients with spiculated findings.